The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease.
The approval is the second for an RSV monoclonal antibody preventive for infants.
Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and flu-associated prescribing exceeding 20% in peak flu years.
A retrospective analysis of hospitalized VA patients finds that prior flu or RSV infection more than doubled the odds of subsequent Streptococcus pneumoniae infection.
The WHO is recommending use of a maternal RSV vaccine and the monoclonal antibody nirsevimab to protect infants against the virus.
Costs varied across 5 European countries, driven primarily by repeated primary care visits and parental work absences.
A total of 11% of RSV patients experienced a cardiac event, abnormal heart rhythm, heart failure, or ischemic heart disease.
A separate study found that 72% of infants were protected against RSV through maternal vaccination or infant receipt of nirsevimab in 2023-24.
Wastewater levels for COVID-19 are low, while for influenza A and RSV they are very low.
For patients with weakened immune systems, effectiveness was lower, at 67% for patients aged 60 to 74 years to 73% for those older than 75.
